JPMorgan Chase & Co. Sells 48,102 Shares of STAAR Surgical (NASDAQ:STAA)

JPMorgan Chase & Co. decreased its position in STAAR Surgical (NASDAQ:STAA - Free Report) by 22.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 166,648 shares of the medical instruments supplier's stock after selling 48,102 shares during the period. JPMorgan Chase & Co. owned approximately 0.34% of STAAR Surgical worth $4,048,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Vanguard Group Inc. boosted its position in shares of STAAR Surgical by 5.8% during the 4th quarter. Vanguard Group Inc. now owns 5,855,570 shares of the medical instruments supplier's stock valued at $142,232,000 after purchasing an additional 319,441 shares in the last quarter. Geode Capital Management LLC lifted its stake in STAAR Surgical by 2.7% in the third quarter. Geode Capital Management LLC now owns 1,174,499 shares of the medical instruments supplier's stock valued at $43,641,000 after buying an additional 31,212 shares during the period. Yunqi Capital Ltd boosted its holdings in shares of STAAR Surgical by 48.9% during the 4th quarter. Yunqi Capital Ltd now owns 767,413 shares of the medical instruments supplier's stock worth $18,640,000 after buying an additional 252,113 shares in the last quarter. Defender Capital LLC. grew its position in shares of STAAR Surgical by 3.5% during the 4th quarter. Defender Capital LLC. now owns 701,567 shares of the medical instruments supplier's stock worth $17,041,000 after buying an additional 23,950 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of STAAR Surgical by 4.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 444,290 shares of the medical instruments supplier's stock valued at $10,792,000 after acquiring an additional 18,168 shares in the last quarter. 96.70% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, major shareholder Broadwood Partners, L.P. acquired 36,532 shares of STAAR Surgical stock in a transaction on Friday, February 14th. The stock was acquired at an average cost of $15.49 per share, with a total value of $565,880.68. Following the transaction, the insider now owns 11,289,437 shares of the company's stock, valued at approximately $174,873,379.13. This trade represents a 0.32 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last 90 days, insiders purchased 1,742,581 shares of company stock worth $28,407,543. 1.00% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several brokerages recently issued reports on STAA. BTIG Research lowered shares of STAAR Surgical from a "buy" rating to a "neutral" rating in a research note on Wednesday, February 12th. William Blair cut shares of STAAR Surgical from an "outperform" rating to a "market perform" rating in a research report on Wednesday, February 12th. Piper Sandler decreased their target price on STAAR Surgical from $40.00 to $16.00 and set a "neutral" rating for the company in a research report on Wednesday, February 12th. Mizuho lowered STAAR Surgical from an "outperform" rating to a "neutral" rating and cut their price target for the stock from $45.00 to $17.00 in a report on Wednesday, February 12th. Finally, StockNews.com cut STAAR Surgical from a "hold" rating to a "sell" rating in a research note on Thursday, February 13th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, STAAR Surgical currently has an average rating of "Hold" and an average price target of $24.25.

STAAR Surgical Stock Performance

Shares of STAAR Surgical stock traded up $0.23 on Wednesday, hitting $17.40. The company had a trading volume of 625,964 shares, compared to its average volume of 794,436. STAAR Surgical has a 1 year low of $13.50 and a 1 year high of $49.86. The stock has a 50 day moving average of $17.10 and a 200-day moving average of $23.09. The stock has a market capitalization of $858.26 million, a price-to-earnings ratio of -42.44 and a beta of 0.75.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.